US5206249A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Bis-naphthalimides containing amino-acid derived linkers as anticancer agents
Assignee: Bristol Myers Squibb Pharma Co
•
Filing: 1991-12-11
•
Granted: 1993-04-27
•
Expires: 2011-12-11
Abstract
Abstract This invention relates to bis-naphthalimides, including 2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]-bis[5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione] and 2,2'-[1,2-ethanediylbis[imino(2-methyl-2,1-ethanediyl)]]-bis[5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione], processes for their preparation, pharmaceutical compositions containing them, and methods of using them to treat cancer in mammals.
Inventors
- 👤 Jung-Hui Sun
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-24 09:32
CPC Classifications
C; C07; C07D; C07D221/00; C07D221/02; C07D221/04; C07D221/06; C07D221/14; A; A61; A61P; A61P35/00; C07C; C07C209/00; C07C209/44; C07C209/50
Claims Analysis
Total Claims: 8
Claim 1
Independent Claim
33 words
A compound, or a pharmaceutically acceptable salt thereof, which si selected from the group consisting of: (S,S)-2,2'-[1,2-ethanedylbis[imino(1-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de ]disoquinoline-1,3(2H)-dione]; (Racemic+Meso)-2,2'-[1,2-ethanedylbis[imino(1-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione; (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de ]isoquinoline-1,3(2H)-dione]; (Meso)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de]isoquinoline-1,3)(2H)-dione]; (S,S)-2,2'-[1,2-ethanediylbis[imino(2-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione]; (Racemic+Meso)-2,2'-[1,2-ethanediylbis[imino(2-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione]; (R,R)-2,2'-[1,2-ethanediylbis[imino(2-methyl-2,1-ethanediyl)]]-bis[5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione]; (Meso)-2,2'-[1,2-ethanediylbis[imino(2-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione].
Claim 2
Dependent Claim
33 words
A compound, or a pharmaceutically acceptable salt thereof, which si selected from the group consisting of: (S,S)-2,2'-[1,2-ethanedylbis[imino(1-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de ]disoquinoline-1,3(2H)-dione]; (Racemic+Meso)-2,2'-[1,2-ethanedylbis[imino(1-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione; (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de ]isoquinoline-1,3(2H)-dione]; (Meso)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de]isoquinoline-1,3)(2H)-dione]; (S,S)-2,2'-[1,2-ethanediylbis[imino(2-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione]; (Racemic+Meso)-2,2'-[1,2-ethanediylbis[imino(2-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione]; (R,R)-2,2'-[1,2-ethanediylbis[imino(2-methyl-2,1-ethanediyl)]]-bis[5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione]; (Meso)-2,2'-[1,2-ethanediylbis[imino(2-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de]isoquinoline-1,3(2H)-dione].
Claim 3
Dependent Claim
13 words
The compound, or a pharmaceutically acceptable salt thereof, which is (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de]isoquinoline-1,3(2l H)-dione].
Claim 4
Dependent Claim
13 words
The compound, or a pharmaceutically acceptable salt thereof, which is (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]-bis [5-nitro-1H-benz[de]isoquinoline-1,3(2l H)-dione].
Claim 5
Dependent Claim
20 words
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective tumor-inhibiting amount of a compound of claim 1.
Claim 6
Dependent Claim
20 words
A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a therapeutically effective tumor-inhibiting amount of a compound of claim 2.
Claim 7
Dependent Claim
29 words
A method of treating a solid tumor carcinoma in a mammal comprising administering to a mammal bearing such a tumor, a tumor-inhibiting amount of a compound of claim 1.
Claim 8
Dependent Claim
29 words
A method of treating a solid tumor carcinoma in a mammal comprising administering to a mammal bearing such a tumor, a tumor-inhibiting amount of a compound of claim 2.
References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1996-04-26 | 1996-10-26 | 1997-04-27 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2000-04-26 | 2000-10-26 | 2001-04-27 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2004-04-26 | 2004-10-26 | 2005-04-27 | $7700.00 | Window Closed / Lapsed |